Trial · NCT00772941
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Risk Factors for the Frequency of Treatment Related Adverse Events - Gender. | 24 weeks | The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. | participants | NUMBER |
| PRIMARY | Risk Factors for the Frequency of Treatment Related Adverse Events - Age. | 24 weeks | The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. | participants | NUMBER |
| PRIMARY | Risk Factors for the Frequency of Treatment Related Adverse Events - Chronic Obstructive Pulmonary Disease as a Complication. | 24 weeks | The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. | participants | NUMBER |
| PRIMARY | Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Drugs. | 24 weeks | The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. | participants | NUMBER |
| PRIMARY | Risk Factors for the Frequency of Treatment Related Adverse Events - Concomitant Therapies. | 24 weeks | The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. | participants | NUMBER |
| PRIMARY | Risk Factors for the Frequency of Treatment Related Adverse Events - Weight at Baseline. | 24 weeks | The safety analysis population consists of the participants who satisfy the case conditions and in whom administration of this drug was confirmed. The number of participants who provided weight data at baseline was 1700. | participants | NUMBER |
| PRIMARY | Risk Factors for the Proportion of Responders - Tobacco Consumption Per Day. | 24 weeks | The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants who provided data on daily tobacco consumption was 2827. | participants | NUMBER |
| PRIMARY | Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks. | 24 weeks | The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants in whom the prolonged administration of Varenicline after 12 weeks was confirmed was 2598. | participants | NUMBER |
| PRIMARY | Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug. | 24 weeks | The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants who provided data on concomitant administration of antipsychotics was 2842. | participants | NUMBER |
| PRIMARY | Number of Participants With Treatment Related Adverse Events. | 24 weeks | No statistical analysis provided for the frequency of treatment related adverse events. | participants | NUMBER |
| PRIMARY | Number of Unlisted Treatment Related Adverse Events According to Japanese Package Insert. | 24 weeks | No statistical analysis provided for the frequency of unlisted treatment related adverse events. | events | NUMBER |
| SECONDARY | Number of Participants With Continuous Abstinence Situation by 52 Weeks. | 52 weeks | No statistical analysis provided for the frequency of Varenicline-dependent treatment related adverse events. | participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00772941/outcomes